시장보고서
상품코드
1129242

세계의 모공성각화증 치료 시장(2022-2029년)

Global Keratosis Pilaris Treatment Market - 2022-2029

발행일: | 리서치사: DataM Intelligence | 페이지 정보: 영문 160 Pages | 배송안내 : 2일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

시장 역학

모공성각화증 치료법의 진보가 시장 성장의 원동력이 될 것으로 예상됩니다.

목차

제1장 조사 방법과 조사 범위

  • 조사 방법
  • 조사 목적 및 조사 범위

제2장 시장의 정의와 개요

제3장 개요

제4장 시장 역학

  • 시장 영향 요인
    • 촉진요인
    • 억제요인
    • 기회
    • 영향 분석

제5장 산업 분석

  • 공급망 분석
  • 가격결정 분석
  • 미충족 요구 분석

제6장 COVID-19 분석

  • COVID-19의 시장 분석
    • COVID-19 이전 시장 시나리오
    • COVID-19의 현재 시장 시나리오
    • COVID-19 이후 또는 향후 시나리오
  • COVID-19 중 가격 역학
  • 수요-공급 스펙트럼
  • 팬데믹시 시장에 관련된 정부 구상
  • 제조업체의 전략적 구상
  • 결론

제7장 모달리티 유형별

  • 시판약
  • 처방전

제8장 치료 유형별

  • 국소 박리제
    • 로션
    • 크림
    • 기타
  • 레티노이드 외용제
    • Tretinoin(Atralin, Avita, Renova, Retin-A)
    • Tazarotene(Avage, Tazorac)
    • 기타
  • 레이저 치료
  • 기타

제9장 판매채널별

  • 병원내 약국
  • 소매 약국
  • 온라인 약국
  • 기타

제10장 지역별

  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 독일
    • 영국
    • 프랑스
    • 이탈리아
    • 스페인
    • 기타 유럽
  • 남미
    • 브라질
    • 아르헨티나
    • 기타 남미 지역
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 호주
    • 기타 아시아태평양
  • 중동·아프리카 지역

제11장 경쟁 구도

  • 주요 개발과 전략
  • 기업 점유율 분석
  • 제품 벤치마킹
  • 주목할 만한 주요 기업 리스트

제12장 기업 개요

  • Neostrata Company, Inc.
    • 기업 개요
    • 제품 포트폴리오와 설명
    • 주요 하이라이트
    • 재무 개요
  • SLMD Skincare
  • Galderma
  • Touch Skin Care
  • Nip+Fab
  • Neutrogena
  • Eucerin
  • AmLactin
  • CeraVe
  • First Aid Beauty

제13장 세계의 모공성각화증 치료 시장 - DataM

KSA 22.10.06

Market Overview

Keratosis Pilaris Treatment market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 4.3 % during the forecast period (2022-2029).

Keratosis pilaris is a common skin ailment that causes small bumps on your arms, legs, or buttocks. Bumps form when there is too much keratin in your skin. Moisturizers and prescription creams are used to assist and improve the appearance of the skin. By the age of 30, the problem normally goes away.

Market Dynamics

Advancement in the treatment of Keratosis Pilaris is expected to drive market growth.

Chlorine dioxide compound is a great antibacterial and anti-inflammatory substance that is non-toxic to humans. It's a dangerous gas at high concentrations. Still, when it's dissolved in water and administered to human tissue, it's inactivated by an intracellular defense mechanism, so there are no adverse effects. In keratosis pilaris, it has been discovered to be an effective cleansing agent. Moreover, it functions as a keratolytic by neutralizing reactive oxygen molecules and destroying the intramolecular and intermolecular disulfide bonds that stabilize keratin. It only reacts with a few specific amino acids and does not oxidize lipids, carbohydrates, or other organic compounds. Cysteine, tyrosine, tryptophan, methionine, proline, hydroxyproline, and histidine are among the amino acids it reacts with, with cysteine, methionine, tyrosine, and tryptophan constituting the majority of its biologic action. Therefore, there is an increased demand for the treatment of Keratosis Pilaris. Thus, from the above statements, the market is expected to drive in the forecast period.

Complications associated with Keratosis Pilaris Treatment are expected to hamper the market growth.

Patients are often distressed about the cosmetic appearance of the condition. Scarring resulting from the patient rupturing the lesions traumatically is another problem that might occur. Lack of awareness about the importance of using the prescribed topical treatments and not manipulating the lesions are some factors the market is expected to hamper in the forecast period.

Global Keratosis Pilaris Treatment Market - Industry Analysis

The keratosis pilaris treatment market provides in-depth analysis of the market based on various industry factors such as porter's five forces, supply chain analysis, reimbursement scenario, product innovation, pricing analysis, etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. SARS-CoV-2-related cutaneous diseases have been on the rise all over the world. Maculopapular rash, vesicular rash, pseudo-chilblain, keratosis pilaris, and urticaria are the five most common patterns associated with these disorders. Moreover, due to limits on non-essential doctor visits and complete lockdown in most countries, diagnosis and treatment rates have decreased dramatically by 2020. In addition, the American Academy of Dermatology was in constant contact with dermatologists to limit the number of patients with non-urgent medical concerns, such as keratosis pilaris, who were allowed to visit.

Additionally, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

Topical Exfoliates segment is expected to hold the largest market share in keratosis pilaris treatment market

The topical exfoliates segment is expected to dominate in 2021. The segment is beneficial because Keratosis pilaris normally disappears on its own over time. In the interim, you can improve the appearance of your skin using any of the many products available. If moisturizing and other self-care measures don't help, your doctor may prescribe medicated creams. For instance, Alpha hydroxy acid, lactic acid, salicylic acid, and urea-containing creams help loosen and eliminate dead skin cells. They also soften and hydrate dry skin. These creams (topical exfoliants) are available over-the-counter or with a prescription, depending on their intensity.

Moreover, the use of a medicated cream daily may help to improve the appearance of the skin. If you stop, though, the problem will return. Keratosis pilaris can linger for years, even after treatment. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global keratosis pilaris Treatment market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of Keratosis Pilaris, rising patient education among the population, advancement in the treatment of Keratosis Pilaris, high rate of adoption of solutions, increase in the number of patients with keratosis pilaris visiting the doctor, as well as new players are focusing on forming partnerships with pharmacies are some of the factors the market is expected to boost in the forecast period. For instance, The appropriate management of keratosis pilaris necessitates patient education. Patients must recognize that keratosis pilaris is a chronic illness with no cure. The physician should also inform the patient that the illness often improves without therapy over time and that treatments are purely cosmetic. Patients must understand that keratosis pilaris is frequently resistant to treatment methods.

Moreover, Keratosis pilaris causes discoloration, which can be improved with laser treatments. Laser treatments are performed by dermatologists who use a laser to target the skin. It's sometimes used to alleviate extreme inflammation and redness. It's not a cure, but it might help when creams and lotions aren't cutting it. This treatment requires numerous sessions to be effective. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the keratosis pilaris treatment market are Neostrata Company, Inc., SLMD Skincare, Galderma, Touch Skin Care, Nip + Fab, Neutrogena, Eucerin, AmLactin, CeraVe, First Aid Beauty.

Neostrata Company, Inc.:

Overview:

NeoStrata Company, Inc., located in Princeton, NJ, develops and markets a comprehensive range of clinically proven, dermatologist-developed skincare brands, including NeoStrata, Exuviance, CoverBlend, NeoCeuticals and NeoStrata Therapeutics. Polyhydroxy Acid technology is used in the company's innovative therapeutic and aesthetic dermatological solutions to fulfill the needs of all skin types. They're sold at consumer stores, doctors' clinics, and spas worldwide. Moreover, AHAs are advantageous in treating dermatological diseases and efficient in spurring prematurely aged or damaged skin to regenerate itself, revolutionizing the treatment of aging skin, according to the company's passion and vision.

Product Portfolio:

GLYCOLIC RENEWAL SERUM: This potent blend of 10% Alpha Hydroxy Acid (AHA) and antioxidants is designed to improve the texture of the skin's surface. Glycolic Acid is formulated to promote surface skin cells' exfoliation while keeping the pH at a healthy level.

The global keratosis pilaris treatment market report would provide an access to an approx. 45+market data table, 40+figures and 160pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Advancement in the treatment of Keratosis Pilaris is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Complications associated with Keratosis Pilaris Treatment are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Modality Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Modality Type
    • 7.1.2. Market Attractiveness Index, By Modality Type Segment
  • 7.2. Over-the-Counter*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Prescription

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 8.2. Topical Exfoliates*
    • 8.2.1. Lotions
    • 8.2.2. Cream
    • 8.2.3. Others
    • 8.2.4. Introduction
    • 8.2.5. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Topical retinoids
    • 8.3.1. Tretinoin (Atralin, Avita, Renova, and Retin-A)
    • 8.3.2. Tazarotene (Avage, Tazorac)
    • 8.3.3. Others
  • 8.4. Laser treatment
  • 8.5. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Modality Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Modality Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Modality Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Modality Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Modality Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Neostrata Company, Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. SLMD Skincare
  • 12.3. Galderma
  • 12.4. Touch Skin Care
  • 12.5. Nip + Fab
  • 12.6. Neutrogena
  • 12.7. Eucerin
  • 12.8. AmLactin
  • 12.9. CeraVe
  • 12.10. First Aid Beauty

LIST NOT EXHAUSTIVE

13. Global Keratosis Pilaris Treatment Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제